Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q3)Sep 30, 2025 | (Q2)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 49.07%240.95K | -120.19%-22.61K | -82.90%126.17K | 338.27%3.01M | 2,023.72%2M | -59.99%161.63K | -25.59%111.99K | 1,829.51%737.73K | 14.04%686.82K | -59.66%94.12K |
| Net income from continuing operations | 189.22%252.69K | 81.22%-61.49K | -43.77%-214.11K | 182.73%1.06M | 740.04%1.82M | -305.52%-283.24K | 47.44%-327.52K | 51.25%-148.92K | 25.33%-1.28M | 83.52%-284.51K |
| Operating gains losses | ---- | ---- | ---- | --54.55K | ---- | ---- | ---- | ---- | ---- | ---- |
| Depreciation and amortization | -24.73%176.45K | -20.59%194.53K | -17.38%205.09K | -27.03%932.41K | -28.25%204.8K | -25.42%234.42K | -26.30%244.97K | -28.21%248.22K | -6.64%1.28M | -21.04%285.41K |
| Remuneration paid in stock | --0 | --0 | --0 | -81.33%13.78K | -88.90%572 | -64.20%4.4K | -77.78%4.4K | -87.95%4.4K | -69.19%73.83K | -82.49%5.15K |
| Deferred tax | ---- | ---- | ---- | --0 | --0 | ---- | ---- | --0 | -100.00%-42 | --0 |
| Other non cashItems | 59.53%20.4K | -92.00%1.61K | -28.97%12.98K | -2,458.84%-2.06M | -10,816.87%-2.11M | -39.20%12.79K | -8.30%20.07K | -25.83%18.27K | 16.40%87.23K | -4.32%19.68K |
| Change In working capital | -204.38%-198.6K | -196.64%-167.25K | -80.15%122.21K | 66.33%882.99K | -240.50%-96.08K | 50.80%190.26K | -56.69%173.07K | 1,073.37%615.75K | 214.88%530.86K | -83.25%68.39K |
| -Change in receivables | 130.39%252.71K | -693.96%-1.16M | 190.90%1.33M | -13.92%-222.18K | -106.79%-41.38K | -141.99%-831.6K | 362.52%195.1K | 217.93%455.69K | -106.80%-195.04K | -69.97%609.34K |
| -Change in inventory | 83.42%-5.39K | -109.76%-9.27K | 338.26%44.74K | -96.16%56.31K | -84.46%12.55K | -155.08%-32.48K | -26.76%95.02K | -101.57%-18.78K | 202.94%1.47M | 105.98%80.75K |
| -Change in prepaid assets | -91.77%3.92K | -34.34%-21.09K | -27.64%21.18K | -90.38%38.9K | -135.56%-22.22K | 161.38%47.55K | 73.16%-15.7K | -92.34%29.27K | 261.89%404.31K | 135.12%62.49K |
| -Change in payables and accrued expense | -200.70%-686.81K | 827.73%972.46K | -461.94%-1.19M | 189.61%967.49K | 113.05%89.41K | 51.53%682.06K | -138.72%-133.63K | 127.71%329.65K | -4,405.28%-1.08M | -452.51%-685.13K |
| -Change in other working capital | -27.03%236.97K | 53.14%49.44K | 57.70%-76.18K | 166.30%42.48K | -14,372.51%-134.45K | 665.16%324.73K | -43.91%32.28K | -176.59%-180.09K | 96.19%-64.07K | 100.33%942 |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 58.19%250.95K | -128.36%-32.61K | -82.90%126.17K | 29.22%887.52K | -231.57%-123.83K | -60.73%158.63K | -23.59%114.99K | 1,829.56%737.73K | 14.04%686.82K | -59.66%94.12K |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | -110.61%-5.14K | 158.59K | -1,616.11%-257.14K | 94.05%-27.82K | 18.28%-61.28K | 251.23%48.45K | 0 | 93.03%-14.98K | -88,390.75%-467.94K | -74.99K |
| Net PPE purchase and sale | ---- | ---- | ---- | --0 | ---48.45K | --48.45K | --0 | --0 | -104.92%-732 | --0 |
| Net intangibles purchas and sale | ---94.66K | --0 | --0 | 94.05%-27.82K | 82.88%-12.84K | --0 | --0 | 93.03%-14.98K | -3,155.13%-467.21K | ---74.99K |
| Net other investing changes | --89.52K | --158.59K | ---257.14K | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | -110.62%-5.14K | --158.59K | -1,616.11%-257.14K | 94.05%-27.82K | 18.28%-61.28K | 251.23%48.45K | --0 | 93.03%-14.98K | -88,390.75%-467.94K | ---74.99K |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 48.01%-220.84K | -525.59%-111.2K | 110.00%64.16K | -122.54%-773.91K | 438.15%266.67K | -42.82%-424.77K | 117.99%26.13K | -469.41%-641.94K | 24.00%-347.76K | 33.16%-78.86K |
| Net issuance payments of debt | 48.01%-220.84K | -525.59%-111.2K | 110.00%64.16K | -122.54%-773.91K | 438.15%266.67K | -42.82%-424.77K | 117.99%26.13K | -469.41%-641.94K | 23.81%-347.76K | 33.16%-78.86K |
| Net other financing activities | ---- | ---- | --1 | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 48.01%-220.84K | -525.60%-111.2K | 110.00%64.16K | -122.54%-773.91K | 438.15%266.67K | -42.82%-424.77K | 117.99%26.13K | -469.41%-641.94K | 24.00%-347.76K | 33.16%-78.86K |
| Net cash flow | ||||||||||
| Beginning cash position | -52.80%64.15K | -97.39%704 | 125.84%86.61K | -51.15%38.35K | -301.29%-46.55K | 399.91%135.89K | -66.49%27.01K | -51.15%38.35K | 25.47%78.51K | -77.54%23.13K |
| Current changes in cash | 111.47%24.96K | -89.53%14.78K | -182.67%-66.81K | 165.79%84.79K | 234.86%80.56K | -392.18%-217.69K | 200.35%141.12K | 2,764.26%80.81K | -188.75%-128.88K | -151.80%-59.73K |
| Effect of exchange rate changes | -127.40%-9.66K | 250.95%48.67K | 79.27%-19.1K | -141.18%-36.53K | -29.82%52.6K | 144.87%35.25K | -136.97%-32.24K | -1,897.64%-92.15K | 168.63%88.73K | 153.63%74.95K |
| End cash Position | 270.68%79.45K | -52.80%64.15K | -97.39%704 | 125.84%86.61K | 125.84%86.61K | -301.29%-46.55K | 399.91%135.89K | -66.49%27.01K | -51.15%38.35K | -51.15%38.35K |
| Free cash from | -1.48%156.29K | -128.36%-32.61K | -82.54%126.17K | 292.78%859.7K | -814.39%-136.67K | -57.35%158.63K | 2,385.28%114.99K | 508.77%722.75K | -62.28%218.88K | -91.80%19.13K |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.